Serum hepcidin in inflammatory bowel diseases: Biological and clinical significance

Inflammatory Bowel Diseases

Volumn 19, Issue 10, 2013, Pages 2166-2172

  Bergamaschi, Gaetano ^a,b   Sabatino, Antonio Di ^a   Albertini, Riccardo ^b   Costanzo, Filippo ^a   Guerci, Marco ^a   Masotti, Michela ^a   Pasini, Alessandra ^a   Massari, Alessandro ^a   Campostrini, Natascia ^c   Corbella, Michela ^c   Girelli, Domenico ^c   Corazza, Gino Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Anemia of inflammation; Hepcidin; Inflammatory bowel disease; Iron deficiency anemia

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEPCIDIN; HEPCIDIN 20; HEPCIDIN 25; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; DISEASE ACTIVITY; ENTERITIS; ERYTHROPOIESIS; FEMALE; HUMAN; INFLAMMATION; IRON DEFICIENCY ANEMIA; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANEMIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HEPCIDINS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84884547856     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31829a6e43     Document Type: Article

References (36)

1. Gasche C, Kulnigg S. Intravenous iron in inflammatory bowel disease. Semin Hematol. 2006;43(suppl 6):S18-S22.
2. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123-130.
3. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of antitumor necrosis factor-alpha treatment. Haematologica. 2010;95:199-205.
4. Ott C, Liebold A, Takses A, et al. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol Res Pract. 2012; 2012:595970.
5. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009;113:5277-5286.
6. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002;48: 1066-1076.
7. Oustamanolakis P, Koutroubakis IE, Kouroumalis EA. Diagnosing anemia in inflammatory bowel disease: beyond the established markers. J Crohns Colitis. 2011;5:381-391.
8. Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142:24-38.
9. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117: 4425-4433.
10. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101: 2461-2463.
11. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science. 2012;338:768-772.
12. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
13. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
14. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
15. Blanc B, Finch CA, Hallberg L, et al. Nutritional anaemias. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1968;405:1-40.
16. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
17. Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997; 89:1052-1057.
18. Theurl I, Mattle V, Seifert M, et al. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood. 2006;107:4142-4148.
19. Bozzini C, Campostrini N, Trombini P, et al. Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis. 2008;40:347-352.
20. Campostrini N, Castagna A, Zaninotto F, et al. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol. 2010;2010:1-7.
21. Campostrini N, Traglia M, Martinelli N, et al. Serum levels of the hepcidin-20 isoform in a large general population: the Val Borbera Study. J Proteomics. 2012;76:28-35.
22. Arnold J, Sangwaiya A, Bhatkal B, et al. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis. Eur J Gastroenterol Hepatol. 2009;21:335-339.
23. Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:262-268.
24. Kroot JJC, Laarakkers CMM, Geurts-Moespot AJ, et al. Immunochemical and mass-spectrometry based serum hepcidin assays for iron metabolism disorders. Clin Chem. 2010;56:1570-1579.
25. Kroot JJC, Kemna EHJM, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica. 2009;94:1748-1752.
26. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006;12:1101-1106.
27. Basseri RJ, Nemeth E, Vassilaki ME, et al. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J Crohns Colitis. 2013;7: e286-e291.
28. Darshan D, Frazer DM, Wilkins SJ, et al. Severe iron deficiency blunts the response of the iron regulatory gene Hamp and pro-inflammatory cytokines to lipopolysaccharide. Haematologica. 2010;95:1660-1667.
29. Theurl I, Schroll A, Nairz M, et al. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica. 2011;96:1761-1769.
30. Weber CS, Beck-da-Silva L, Goldraich LA, et al. Anemia in heart failure: association of hepcidin levels to iron deficiency in stable outpatients. Acta Haematol. 2013;129:55-61.
31. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117:e218-e225.
32. Traglia M, Girelli D, Biino G, et al. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet. 2011;48: 629-634.
33. Cherayil BJ, Ellenbogen S, Shanmugam NN. Iron and intestinal immunity. Curr Opin Gastroenterol. 2011;27:523-528.
34. Wang L, Trebicka E, Fu Y, et al. The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:112-119.
35. Maisetta G, Petruzzelli R, Brancatisano FL, et al. Antimicrobial activity of human hepcidin 20 and 25 against clinically relevant bacterial strains: effect of copper and acidic pH. Peptides. 2010;31:1995-2002.
36. Tavanti A, Maisetta G, Del Gaudio G, et al. Fungicidal activity of the human peptide 20 alone or in combination with other antifungals against Candida glabrata isolates. Peptides. 2011;32:2484-2487.